UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported) | March 24, 2011 |
| THE PROCTER & GAMBLE COMPANY |
| (Exact name of registrant as specified in its charter) |
| Ohio | | 1-434 | | 31-0411980 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
| One Procter & Gamble Plaza, Cincinnati, Ohio | | 45202 |
| (Address of principal executive offices) | | Zip Code |
| (513) 983-1100 | | 45202 |
| (Registrant's telephone number, including area code) | | Zip Code |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 7.01 REGULATION FD DISCLOSURE
On March 24, 2011, The Procter & Gamble Company (“Company”) and Teva Pharmaceutical Industries Ltd. issued a news release announcing that the
companies have reached an agreement to created a partnership in consumer health care by bringing together both companies' existing over-the-counter
medicines and complementary capabilities. The Company is furnishing this 8-K pursuant to Item 7.01, "Regulation FD Disclosure."
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
BY: /s/ E.J. WUNSCH
E.J. Wunsch
Assistant Secretary
March 24, 2011
EXHIBITS
| 99 | News Release by The Procter & Gamble Company dated March 24, 2011 |
